Calliditas Therapeutics AB (publ)
NASDAQ Global SelectTotal Valuation
Calliditas Therapeutics AB (publ) carries a market capitalization of 2.15B, placing it among publicly traded companies globally. Its enterprise value stands at 11.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.15B |
| Enterprise Value | 11.35B |
Share Statistics
Calliditas Therapeutics AB (publ) currently has 54.01M shares outstanding.
| Shares Outstanding | 54.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 6.96 |
| PB Ratio | N/A |
| P/TBV Ratio | -30.54 |
| P/FCF Ratio | -45.50 |
| P/OCF Ratio | -45.50 |
Enterprise Valuation
| EV / Sales | 7.09 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Calliditas Therapeutics AB (publ) maintains a current ratio of 2.69, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 944.17, indicating elevated leverage, while an interest coverage ratio of -8.95 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.69 |
| Quick Ratio | 2.59 |
| Debt / Equity | 944.17 |
| Debt / EBITDA | -2.59 |
| Interest Coverage | -8.95 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -27.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.62 |
Taxes
| Income Tax | 12.04M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Calliditas Therapeutics AB (publ)'s stock has gained approximately 129.16127% over the past 52 weeks. The 50-day moving average sits at 39.65, while the 200-day moving average is 29.60.
| Beta (5Y) | N/A |
| 52-Week Price Change | 129.16127% |
| 50-Day Moving Average | 39.65 |
| 200-Day Moving Average | 29.60 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Calliditas Therapeutics AB (publ) generated 1.60B in revenue and converted that into -480.36M in net income, yielding earnings per share of -17.90. EBITDA reached -389.50M, while operating income came in at -389.50M.
| Revenue | 1.60B |
| Gross Profit | 1.50B |
| Operating Income | -389.50M |
| Pretax Income | -468.32M |
| Net Income | -480.36M |
| EBITDA | -389.50M |
| EBIT | -389.50M |
| Earnings Per Share (EPS) | -17.90 |
Balance Sheet
Calliditas Therapeutics AB (publ) holds 797.28M in cash and equivalents against 1.01B in total debt, resulting in a net debt position of 185.21M.
| Cash & Cash Equivalents | 797.28M |
| Total Debt | 1.01B |
| Net Debt | 185.21M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 724.69M |
Cash Flow
Calliditas Therapeutics AB (publ) produced -244.93M in operating cash flow over the past twelve months.
| Operating Cash Flow | -244.93M |
| Capital Expenditures | N/A |
| Free Cash Flow | -244.93M |
| FCF Per Share | -9.13 |
Margins
Calliditas Therapeutics AB (publ) operates with a gross margin of 93.46, reflecting its pricing power and cost economics. The operating margin of -24.32 and net profit margin of -30.00 provide insight into operational efficiency.
| Gross Margin | 93.46 |
| Operating Margin | -24.32 |
| Pretax Margin | -29.24 |
| Profit Margin | -30.00 |
| EBITDA Margin | -24.32 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.76 |
| FCF Yield | -2.20 |
Scores
Calliditas Therapeutics AB (publ) posts an Altman Z-Score of 5.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.01 |